NCT03167723

Brief Summary

Traumatic hemothorax and hemopneumothorax are common diagnoses which are typically treated by placement of a chest tube. 28-32 Fr chest tubes have previously been shown equivalent to 36-40 Fr chest tubes for the non-emergent drainage of hemothorax. A smaller study has found 14 Fr pigtails had less pain than larger tubes but was not powered to compare outcomes. We seek to perform a prospective randomized trial that is adequately powered comparing efficacy of 14 Fr thal tubes to 28 Fr chest tubes for non-emergent drainage of hemothorax and hemopneumothorax. Additionally, we will employ maximal barrier precautions for all chest tube insertions and compare empyema rates to our historical controls.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
193

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2017

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 8, 2017

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

May 24, 2017

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 30, 2017

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 20, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 20, 2021

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

March 29, 2023

Completed
Last Updated

March 29, 2023

Status Verified

August 1, 2022

Enrollment Period

4.6 years

First QC Date

May 24, 2017

Results QC Date

November 30, 2022

Last Update Submit

March 6, 2023

Conditions

Keywords

Chest tube sizeHemothoraxEmpyema

Outcome Measures

Primary Outcomes (1)

  • Number of Participants With Retained Hemothorax Following Initial Chest Tube Placement Requiring Intervention

    Number of Participants with Retained hemothorax requiring an additional intervention, either video-assisted thoracoscopic surgery (VATS) or additional thoracostomy tube placement.

    90 days

Secondary Outcomes (9)

  • Duration of Chest Tube Placement.

    90 days

  • Number of Participants Stratified by Length of Hospitalization Stay

    90 days

  • Change in Subjective Pain Scores From Baseline at 90 Days

    90 days

  • Hemodynamic Stability Post-insertion

    90 days

  • Initial Drainage From Chest Tube at 5 Minutes

    5 Minutes

  • +4 more secondary outcomes

Study Arms (2)

28 French chest tube for hemothorax

EXPERIMENTAL

28 French straight chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax

Device: Chest tube placement

14 French chest tube for hemothorax

EXPERIMENTAL

14 French thal chest tube placed for non-emergent drainage of hemothorax or hemopneumothorax

Device: Chest tube placement

Interventions

Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.

14 French chest tube for hemothorax28 French chest tube for hemothorax

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient is admitted to the trauma service.
  • The patient has a hemothorax and/or or hemopneumothorax, requiring thoracostomy tube placement.
  • Thoracostomy tube placement is able to be performed or witnessed by an investigator listed on the study.
  • The patient has not had a chest tube in the past year.
  • The patient is \>18 years of age.
  • In the event the patient is decisionally impaired, consent will be obtained from the individual's legally authorized representative (LAR) or from the individual's healthcare power of attorney (HPA).
  • In the instance of reversible impairment, initial consent would be obtained from the LAR/HPA and the patient will be approached for consent once he/she is deemed mentally competent by the care provider.

You may not qualify if:

  • The patient is incarcerated
  • The patient is known to be pregnant
  • The patient is \< 18 years of age
  • The patient is hemodynamically unstable, requiring emergent chest tube placement (in \<10 minutes from evaluation).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Carolinas Medical Center

Charlotte, North Carolina, 28203, United States

Location

Related Publications (4)

  • Karmy-Jones R, Holevar M, Sullivan RJ, Fleisig A, Jurkovich GJ. Residual hemothorax after chest tube placement correlates with increased risk of empyema following traumatic injury. Can Respir J. 2008 Jul-Aug;15(5):255-8. doi: 10.1155/2008/918951.

    PMID: 18716687BACKGROUND
  • Inaba K, Lustenberger T, Recinos G, Georgiou C, Velmahos GC, Brown C, Salim A, Demetriades D, Rhee P. Does size matter? A prospective analysis of 28-32 versus 36-40 French chest tube size in trauma. J Trauma Acute Care Surg. 2012 Feb;72(2):422-7. doi: 10.1097/TA.0b013e3182452444.

  • Kulvatunyou N, Erickson L, Vijayasekaran A, Gries L, Joseph B, Friese RF, O'Keeffe T, Tang AL, Wynne JL, Rhee P. Randomized clinical trial of pigtail catheter versus chest tube in injured patients with uncomplicated traumatic pneumothorax. Br J Surg. 2014 Jan;101(2):17-22. doi: 10.1002/bjs.9377.

  • McCartt J, Ross SW, Cunningham KW, Wang H, Sealey L, Brake J, Christmas A, Sachdev G, Green J, Thomas BW. A Randomized Non-Inferiority Clinical Trial of 14Fr Thal versus 28Fr Tube Thoracostomy for Traumatic Hemothorax. Am Surg. 2025 Apr;91(4):579-586. doi: 10.1177/00031348241308907. Epub 2024 Dec 19.

MeSH Terms

Conditions

HemothoraxHemopneumothoraxEmpyema

Condition Hierarchy (Ancestors)

Pleural DiseasesRespiratory Tract DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSuppurationInfectionsInflammation

Results Point of Contact

Title
Bradley Thomas MD
Organization
Atrium Health Wake Forest

Study Officials

  • Bradley W Thomas, MD

    Wake Forest University Health Sciences

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Masking Details
Investigator masked to outcomes data.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2017

First Posted

May 30, 2017

Study Start

May 8, 2017

Primary Completion

December 20, 2021

Study Completion

December 20, 2021

Last Updated

March 29, 2023

Results First Posted

March 29, 2023

Record last verified: 2022-08

Data Sharing

IPD Sharing
Will not share

Locations